Containment Dermatology Manufacturing 
XTalks
JULY 16, 2021
Related: Google Launches AI-Based Dermatology Assist Tool. In 2019, lots of losartan potassium/hydrochlorothiazide were recalled after they were found to contain above acceptable levels of the suspected cancer-causing compound N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). Benzene is a colorless flammable liquid that has a sweet odor.
XTalks
AUGUST 7, 2023
Verrica, a company specializing in dermatology therapeutics, has designed Ycanth to be delivered through a single-use applicator. ’s berdazimer gel, containing 10.3 Ycanth (cantharidin) topical solution, developed by Verrica Pharmaceuticals Inc., Another noteworthy contender is Novan Inc.’s
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 4, 2020
(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.
The Pharma Data
DECEMBER 15, 2020
Klisyri will be manufactured by Athenex, highlighting the vertically integrated capabilities of the company ranging from a preclinical lead to a developed product for market launch. We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.
The Pharma Data
AUGUST 19, 2020
Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5
The Pharma Data
OCTOBER 26, 2020
They need additional treatment options that alleviate the symptoms most important to them,” said Jonathan Silverberg, MD, PhD, MPH, Department of Dermatology, The George Washington University School of Medicine and Health Sciences. DISCLOSURE NOTICE: The information contained in this release is as of October 27, 2020. Dermatology.
Bioengineer
JULY 20, 2021
Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Octagam® 10% does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer Octagam® 10% at the minimum infusion rate practicable. About the Octapharma Group.
Expert insights. Personalized for you.
105 
Let's personalize your content